Handelsbanken Fonder AB Has $1.37 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Handelsbanken Fonder AB lifted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 23.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,095 shares of the medical instruments supplier’s stock after acquiring an additional 3,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Haemonetics were worth $1,374,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of HAE. Commonwealth Equity Services LLC raised its holdings in Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock valued at $304,000 after acquiring an additional 117 shares in the last quarter. QRG Capital Management Inc. lifted its position in Haemonetics by 6.9% during the second quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 260 shares during the period. Arizona State Retirement System lifted its position in Haemonetics by 2.0% during the second quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after purchasing an additional 272 shares during the period. State of Michigan Retirement System grew its stake in Haemonetics by 2.5% during the first quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock worth $1,065,000 after buying an additional 300 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC increased its holdings in Haemonetics by 2.1% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock valued at $1,562,000 after buying an additional 374 shares during the period. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HAE shares. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Bank of America initiated coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. BTIG Research started coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price for the company. Citigroup reduced their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Monday, September 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $106.14.

Haemonetics Trading Up 0.7 %

Shares of HAE stock opened at $74.97 on Friday. The company’s fifty day simple moving average is $76.63 and its two-hundred day simple moving average is $83.92. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of 32.74, a PEG ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same quarter last year, the firm posted $1.05 earnings per share. The firm’s revenue was up 8.0% on a year-over-year basis. As a group, analysts anticipate that Haemonetics Co. will post 4.57 earnings per share for the current year.

Insider Transactions at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at $1,658,565.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is currently owned by company insiders.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.